AKTX-101 shows promising synergy in KRAS-driven pancreatic cancer trials
Akari Therapeutics announced positive preclinical findings for AKTX-101 at ASCO 2026, highlighting synergistic activity with KRAS inhibitors in treating difficult pancreatic cancer models. This differentiation from conventional ADCs opens new therapeutic possibilities and extends the application of RNA splicing therapies. Investors should monitor subsequent clinical developments as AKTX-101 progresses towards human trials.
View signal analysis